MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-14-2025
cbdMD Interest Expense 2011-2025 | YCBD
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense cbdMD
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -29.5 K | 63.7 K | 239 K | 29.5 K | 39.9 K | 75.1 K | 955 | 501 K | 155 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 501 K | -29.5 K | 119 K |
Quarterly Interest Expense cbdMD
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.41 K | 7.64 K | 11.4 K | - | -12.7 K | -18.4 K | -418 | - | 9.72 K | 17.8 K | 29.1 K | 137 K | 64.4 K | 2.25 K | 70.7 K | - | -2.58 K | -10.6 K | -10.4 K | 46.3 K | 3.44 K | -10.4 K | 7.27 K | 50.2 K | -14.2 K | -18.1 K | -44 K | 737 | 232 | -44 K | 259 | 500 K | 229 K | -259 | -132 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 500 K | -132 K | 27.5 K |
Interest Expense of other stocks in the Drug manufacturers industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
10.2 M | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
2.78 M | $ 0.74 | -3.53 % | $ 52.6 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-27.9 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
74.6 M | $ 1.64 | -5.64 % | $ 176 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
1.12 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.92 K | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
1.42 M | - | 10.11 % | $ 58.2 M | USA |
 |
Catalent
CTLT
|
-4 M | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
20.1 M | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
2.24 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
4.04 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
350 M | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
87.9 M | $ 12.12 | 6.13 % | $ 621 M | USA |
 |
Evoke Pharma
EVOK
|
500 K | $ 10.96 | 0.09 % | $ 36.6 M | USA |
 |
Athenex
ATNX
|
25.8 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
13 M | $ 21.4 | 0.16 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
127 K | $ 7.16 | 1.7 % | $ 444 M | USA |
 |
Harrow Health
HROW
|
21.3 M | $ 46.04 | -2.17 % | $ 1.5 B | USA |
 |
China Pharma Holdings
CPHI
|
27.4 K | $ 1.55 | -0.26 % | $ 27.1 M |  China |
 |
Bausch Health Companies
BHC
|
-28 M | $ 6.86 | -0.87 % | $ 2.5 B | Canada |
 |
Lannett Company
LCI
|
58 M | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
20 K | $ 4.78 | -0.93 % | $ 629 M | USA |
 |
Pacira BioSciences
PCRX
|
-373 K | $ 26.49 | 0.76 % | $ 1.23 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
606 K | $ 3.02 | 19.37 % | $ 42.5 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
12 K | - | - | $ 193 M | Canada |
 |
Rockwell Medical
RMTI
|
2.3 M | $ 0.88 | -5.2 % | $ 20.5 M | USA |
 |
Solid Biosciences
SLDB
|
652 K | $ 5.8 | -1.28 % | $ 237 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-10 K | $ 3.51 | -2.11 % | $ 4.36 M | USA |
 |
PetIQ
PETQ
|
38.3 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.15 M | $ 4.34 | 6.9 % | $ 131 M | USA |
 |
Jupiter Wellness
JUPW
|
-5.37 M | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
900 K | $ 12.83 | -2.36 % | $ 1.76 B | USA |
 |
ProPhase Labs
PRPH
|
764 K | $ 0.11 | -2.7 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
18.3 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
9.96 M | - | -4.76 % | $ 65.3 M | USA |
 |
Veru
VERU
|
862 K | $ 2.44 | 0.83 % | $ 329 M | USA |
 |
Sundial Growers
SNDL
|
81 K | $ 1.94 | -12.22 % | $ 3.37 M | Canada |
 |
OptiNose
OPTN
|
19.5 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
3.13 M | $ 0.64 | -0.56 % | $ 30.6 M | USA |
 |
Tricida
TCDA
|
17.6 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
46.6 M | $ 11.11 | -8.56 % | $ 6.87 B | Canada |
 |
TherapeuticsMD
TXMD
|
300 K | $ 1.73 | -1.14 % | $ 18.1 M | USA |
 |
Zomedica Corp.
ZOM
|
175 K | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
592 M | $ 11.69 | 0.34 % | $ 14.2 B | USA |